Mobile

A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line ther...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-000175-42

A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with advanced gastric cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the overall survival (OS) for patients treated with capecitabine and cisplatin combined with bevacizumab, versus capecitabine and cisplatin plus placebo (for bevacizumab).

Critère d'inclusion

  • Adult and elderly patients with histologically confirmed, inoperable, locally advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, who have received no prior treatment for advanced or metastatic gastric cancer

Liens